Secukinumab: A Silver Lining in Dermatology
Loading...
Date
2022-07
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
SAGE Publications
Abstract
Secukinumab, a fully human monoclonal antibody, is a biological agent that targets interleukin-17A. Secukinumab is used in the management of the common dermatological entity - plaque-type psoriasis and its various types, namely psoriatic arthritis, hypertrophic palmoplantar psoriasis and generalized pustular psoriasis. Other less common indications of this popular interleukin -17A inhibitor, secukinumab include ankylosing spondylitis, rheumatoid arthritis, systemic lupus erythematosus, Familial Mediterranean fever, and tumor necrosis factor receptor-associated periodic syndrome (TRAPS). This review article was written by referring to various review articles, original articles, and some books related to highly regarded databases, such as the Web of Science, PubMed, and Scopus. The keywords explored during review of literature consisted of combinations of the following words: human monoclonal antibody, IL-17A, and biologicals. The authors with this in-depth review hope to explore the working of this versatile biological, Secukinumab, especially as a silver lining in dermatology
Description
Keywords
Secukinumab, IL-17A inhibitor, Human monoclonal antibody, Biologicals, Psoriasis, Psoriatic arthritis
Citation
Manoharan D, N. RV, Shreya S, Suzsmi L. S.. Secukinumab: A Silver Lining in Dermatology. Journal of Pharmacology and Pharmacotherapeutics. 2022 Jul; 13(2): 119–124